University of Georgia College of Pharmacy, Augusta, GA 30912, USA.
J Palliat Med. 2013 Apr;16(4):409-11. doi: 10.1089/jpm.2012.0424. Epub 2013 Mar 11.
Converting between the various opioid agents continues to be challenge for many practitioners. Specifically, variable recommendations for converting to the transdermal fentanyl patch may lead to confusion among clinicians and errors in dosing.
Our aim was to describe the inconsistencies among available opioid conversions with regard to transdermal fentanyl and to provide recommendations for safe and effective utilization of this product in patients with chronic pain.
Available reports support the use of the morphine intravenous to oral ratio of 1:3 during the conversion to transdermal fentanyl product.
Underdosing is an often overlooked complication of switching to transdermal fentanyl. Current recommendations for converting to transdermal fentanyl do not reflect contemporary clinical practice and should be reevaluated.
对于许多从业者来说，在各种阿片类药物之间进行转换仍然是一个挑战。具体而言，转换为透皮芬太尼贴剂的建议各不相同，这可能导致临床医生感到困惑，并导致用药错误。
我们的目的是描述在透皮芬太尼方面，各种可用的阿片类药物转换之间的不一致之处，并为慢性疼痛患者安全有效地使用该产品提供建议。
现有报告支持在转换为透皮芬太尼产品时，将静脉注射吗啡与口服吗啡的比例设定为 1:3。
剂量不足是转换为透皮芬太尼时经常被忽视的并发症。目前关于转换为透皮芬太尼的建议并未反映当代临床实践，应重新评估。
